With 70% of small molecule drug candidates classified as poorly soluble (BCS Class II and IV), achieving adequate absorption in the gastrointestinal (GI) tract remains a critical challenge in drug development. This webinar delves into effective formulation strategies to overcome these solubility and bioavailability hurdles.
Join us as we explore the latest advancements in bioavailability enhancement technologies, including hot melt extrusion (HME) and spray dried dispersion (SDD), which are gaining momentum in the industry. We’ll discuss the critical factors to consider when selecting the optimal formulation approach during the late discovery and pre-clinical phases, emphasizing that no single solution fits all scenarios.
The session will include:
- A comprehensive review of current and emerging bioavailability enhancement technologies
- Key considerations for leveraging HME and SDD to streamline development
- Real-world case studies demonstrating how strategic formulation approaches can reduce development timelines by up to 50% toward IND filing